article 3 months old

Ramsay Preferred Among Private Hospital Plays

Australia | May 01 2006

By Chris Shaw (Tokyo)

Last week the Federal government introduced changes to legislation regarding health insurance, part of which reflects the likely decision to sell health insurer Medibank Private.

Deutsche Bank suggests there are both positive and negative implications from the proposed changes, though in its view the final result is unlikely to be significant for the private hospital players.

The proposal to increase private health cover fees only after ministerial approval should have little impact in the broker’s view, as essentially that matches the current situation. There may be some downward pressure on premiums though from the proposal to require health insurers to provide more detailed information regarding available services, making this change a minor negative in the broker’s view.

Offsetting this is the proposal to remove the lifetime cover penalties on members who maintain their membership for more than ten years, as well as the expansion of the services included under hospital cover.

The second clearly is of more importance to the private hospital players, as the ability to both offer new services such as outpatient and out-of-hospital services increases the way they can earn fees, while potentially also allowing for the shorter patient stays, that again creates the prospect of higher revenues.

Given the sectoral implications appear mixed at best, the broker’s top stock among the private hospital players remains Ramsay Healthcare (RHC) for its EPS growth profile. The growth will come from the generation of synergies as the company absorbs the Affinity acquisition, while it also offers expansion potential through a number of brownfields opportunities, Deutsche Bank says.

At the same time the broker notes one risk, which stemmed from a high gearing level post the Affinity acquisition, has been put to rest by management’s asset sale program, which has seen gearing drop back to more comfortable levels.

The broker rates the stock as Buy with a price target of $11.00, while elsewhere in the healthcare sector it also rates CSL (CSL) as Buy but has a Hold recommendation on Healthscope (HSP).

The FN Arena database shows the market is slightly positive on Ramsay, as it is rated as Buy by four brokers and equity researchers compared to one Accumulate rating and three Hold recommendations. The average target price on the stock is $10.85.

The last closing price for RHC was $10.70.

To share this story on social media platforms, click on the symbols below.

Click to view our Glossary of Financial Terms

Australian investors stay informed with FNArena – your trusted source for Australian financial news. We deliver expert analysis, daily updates on the ASX and commodity markets, and deep insights into companies on the ASX200 and ASX300, and beyond. Whether you're seeking a reliable financial newsletter or comprehensive finance news and detailed insights, FNArena offers unmatched coverage of the stock market news that matters. As a leading financial online newspaper, we help you stay ahead in the fast-moving world of Australian finance news.